SCHEMBL4908696

SCHEMBL4908696

O=C(Nc1cccc2sc(Nc3ccccc3)nc12)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KDR P35968 2/20 0.51
GAA P10253 2/20 0.51
PKM P14618 1/20 0.51
CASP3 P42574 2/20 0.49
SENP7 Q9BQF6 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 5/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SCD O00767 2/20 0.48
SENP8 Q96LD8 1/20 0.48
TNIK Q9UKE5 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14006462 0.93 SCD (0.56) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4922841 0.93 CHRM4 (0.56) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4918817 0.90 LCK (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4919395 0.90 SCD (0.57) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL14034418 0.90 LCK (0.46) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4919320 0.90 EPM2A (0.48) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4916854 0.88 LCK (0.54) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL14006470 0.88 LCK (0.49) NPC1RAB9AMEN1KMT2ASCD
SCHEMBL14034255 0.88 LCK (0.45) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4914636 0.88 MEN1 (0.53) MEN1KMT2AMAPTTNIKPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US claimed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 NPC1 1580/4885RAB9A 2954/4885MEN1 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.